Results of Malnutrition Correction in Children with Cystic Fibrosis with Hypercaloric Formulas for Enteral Nutrition for One Month: Cohort Study

Background. The use of hypercaloric formulas in cystic fibrosis patients has the risks of negative effects on carbohydrate and lipid metabolism. Thus, it is interesting to analyze the efficacy of malnutrition correction and the safety of hypercaloric enteral products with a low glycemic index and with medium-chain triglycerides content of 50%.

Objective. The aim of the study is analyze the efficacy of malnutrition correction with therapeutic hypercaloric product for enteral nutrition in children with cystic fibrosis.

Methods. The study included patients aged from 3 to 18 years with malnutrition (BMI < 50 percentile) who were prescribed therapeutic hypercaloric formula to correct the malnutrition. Anthropometric indicators (height, body weight), actual nutritional status, pancreatin doses, lung function, carbohydrate metabolism rates, and cholestasis marker (bile acid concentration) were measured initially and after 1 month of using formula nutrition.

Results. The children’ body weight (Me) has increased from 24.5 (21.2; 38.7) to 25.3 kg (21.6; 39.7) (p = 0.001), growth (Me) — from 133.5 (120.2; 146.5) to 136.5 cm (123.0; 148.5) (p < 0.001) after 1 month of using hypercaloric formula. The growth percentile increased from 33 to 40, the z-criterion values — from –0.5 to –0.3 SD (p < 0.001). There was no increase in BMI in dynamics due to the fact that the growth of children was ahead of body weight increase. The daily energy intake increased by an average of 450 kcal that was 21.8% regarding physiological need.

Conclusion. The inclusion of hypercaloric formula in the diet of children with cystic fibrosis for 1 month significantly increases the indicators of linear growth and positively affects the overall physical development. There were no negative effect of formula on carbohydrate and lipid metabolism.

1. Calvo-Lerma J, Hulst J, Boon M, et al. Contribution of Food Groups to Macronutrient Intake in Children with Cystic Fibrosis: A European Multicenter Assessment. J Acad Nutr Diet. 2019; 119(8):1305–1319. doi: 10.1016/j.jand.2019.01.003

2. Calvo-Lerma J, Hulst J, Asseiceira I, et al. Nutritional status, nutrients intake and enzymatic supplements in a European CF cohort: a cross-sectional overview. J Cyst Fibros. 2016;15(1):S3.

3. Calvo-Lerma J, Hulst J, Asseiceira I, et al. Nutritional status, nutrient intake and use of enzyme supplements in paediatric patients with Cystic Fibrosis; a European multicentre study with reference to current guidelines. J Cyst Fibros. 2017;16(4):510–518. doi: 10.1016/j.jcf.2017.03.005

4. Maksimycheva TYu, Kondrateva EI, Sorvacheva TN. Assessment and correction of nutritional status in children with cystic fibrosis. Clinical Practice in Pediatrics. 2018;13(5):24–32. (In Russ). doi: 10.20953/1817-7646-2018-5-24-32

5. Kistoznyi fibroz (mukovistsidoz): Clinical guidelines. Ministry of Health of the Russian Federation; 2021. (In Russ).

6. Mukoviscidoz. Kapranov NI, Kashirskaya NYu, eds. Moscow; 2014. 672 p. (In Russ).

7. Turck D, Braegger CP, Colombo C, et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 2016;35(3):557–577. doi: 10.1016/j.clnu.2016.03.004

8. Kondrat’eva EI, Kashirskaya NYu, Kapranov NI. Natsional’nyi konsensus. Mukovistsidoz: opredelenie, diagnosticheskie kriterii, terapiya. Moscow; 2016. 205 p. (In Russ).

9. Kondrateva EI, Yankina GN, Loshkova EV Experience of using a specialized mixture for enteral nutrition in children with nutritive deficiency. Pediatria. Journal n.a. G.N. Speransky. 2016;95(4): 98–103. (In Russ).

10. Kondrat’eva EI. Enteral nutrition in mucoviscidosis. Pediatric Nutrition. 2015;13(2):22–34. (In Russ).

11. Bushueva TV, Borovik TE, Roslavtseva EA, et al. The application of domestic specialized mixtures for enteral nutrition in children with bronchopulmonary pathology. Rossiiskii Pediatricheskii Zhurnal = Russian Pediatric Journal. 2021;24(2):78–85. (In Russ). doi: 10.46563/1560-9561-2021-24-2-78-85

12. Smyth RL, Rayner O. Oral calorie supplements for cystic fibrosis. Cochrane Database Syst Rev. 2014;(11):CD000406. doi: 10.1002/14651858.CD000406.pub4

13. WHO AnthroPlus for personal computers Manual: Software for assessing growth of the world’s children and adolescents. Geneva: World Health Organization; 2009.

14. Maksimycheva TY, Kondratyeva EI, Sorvacheva TN, Odinaeva ND. Experience of correcting nutritional status in children with cystic fibrosis using computer systems and network communications. Siberian Medical Review. 2019;(4):67–73. (In Russ). doi: 10.20333/2500136-2019-4-67-73

15. Order of the Ministry of Health of the Russian Federation of August 5, 2003 N 330 “O merakh po sovershenstvovaniyu lechebnogo pitaniya v lechebno-profilakticheskikh uchrezhdeniyakh Rossiiskoi Federatsii” (Appendix 5). (In Russ).

16. Polgar G, Promadhat V. Pulmonary function testing in children: Techniques and standards. Philadelphia: W.B. Saunders Co; 1971.

17. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402. Russian version. (In Russ).

18. Martinchik A.N., Maev I.V., Petukhov A.B. Pitanie cheloveka. Osnovy nutritsiologii. Moscow: Federal State Budgetary Institution of Continuing Professional Education “All-Russian Educational, Scientific and Methodological Center for Continuing Medical and Pharmaceutical Education” of the Ministry of Health of the Russian Federation; 2002. 576 p. (In Russ).

19. Woestenenk, JW, Hoekstra T, Hesseling C, et al. Comparison of height for age and height for bone age with and without adjustment for target height in pediatric patients with CF. J Cyst Fibros. 2011;10(4):272–277. doi: 10.1016/j.jcf.2011.03.003

20. Vieni G, Faraci S, Collura M, et al. Stunting is an independent predictor of mortality in patients with cystic fibrosis. Clin Nutr. 2013;32(3):382–385. doi: 10.1016/j.clnu.2012.08.017

21. Assael BM, Casazza G, Iansa P, et al. Milani Growth and long-term lung function in cystic fibrosis: a longitudinal study of patients diagnosed by neonatal screening. Pediatr Pulmonol. 2009;44(3):209–215. doi: 10.1002/ppul.21001